Literature DB >> 14984510

Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome.

A Sefcick, D Sowter, E DasGupta, N H Russell, J L Byrne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14984510     DOI： 10.1046/j.1365-2141.2003.04801.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

1.  A young man with persistent eosinophilia.

Authors:  E Messa; D Cilloni; G Saglio
Journal:  Intern Emerg Med       Date:  2007-06       Impact factor: 3.397

Review 2.  Advances in diagnosis and treatment of eosinophilia.

Authors:  Javed Sheikh; Peter F Weller
Journal:  Curr Opin Hematol       Date:  2009-01       Impact factor: 3.284

Review 3.  Primary eosinophilic disorders: a concise review.

Authors:  Animesh Pardanani; Ayalew Tefferi
Journal:  Curr Hematol Malig Rep       Date:  2008-01       Impact factor: 3.952

Review 4.  Novel targeted therapies for eosinophilic disorders.

Authors:  Michael E Wechsler; Patricia C Fulkerson; Bruce S Bochner; Gail M Gauvreau; Gerald J Gleich; Tim Henkel; Roland Kolbeck; Sameer K Mathur; Hector Ortega; Jatin Patel; Calman Prussin; Paolo Renzi; Marc E Rothenberg; Florence Roufosse; Dagmar Simon; Hans-Uwe Simon; Andrew Wardlaw; Peter F Weller; Amy D Klion
Journal:  J Allergy Clin Immunol       Date:  2012-09       Impact factor: 10.793

Review 5.  Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis.

Authors:  Jason Gotlib
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 6.  Clinical overview of cutaneous features in hypereosinophilic syndrome.

Authors:  Sabine Gisela Plötz; Bettina Hüttig; Birgit Aigner; Christian Merkel; Knut Brockow; Cezmi Akdis; Ulf Darsow; Johannes Ring
Journal:  Curr Allergy Asthma Rep       Date:  2012-04       Impact factor: 4.806

7.  Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody.

Authors:  Paolo Strati; Jorge Cortes; Stefan Faderl; Hagop Kantarjian; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-11-01

Review 8.  [Eosinophilic dermatoses].

Authors:  G Wozel
Journal:  Hautarzt       Date:  2007-04       Impact factor: 0.751

9.  Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia.

Authors:  Srdan Verstovsek; Ayalew Tefferi; Hagop Kantarjian; Taghi Manshouri; Raja Luthra; Animesh Pardanani; Alfonso Quintás-Cardama; Farhad Ravandi; Pat Ault; Carlos Bueso-Ramos; Jorge E Cortes
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531

10.  Hypereosinophilia: a diagnostic dilemma.

Authors:  Habib Ur Rehman
Journal:  J Clin Med Res       Date:  2010-10-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.